New pill HQP1351 enters human testing for stubborn cancers

NCT ID NCT03594422

Recruiting now Disease control Sponsor: Ascentage Pharma Group Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial is testing an oral drug called HQP1351 in about 100 people with advanced gastrointestinal stromal tumors (GIST) or other solid tumors. The main goal is to find a safe dose and see how the body handles the drug. Participants take the pill every other day for four weeks per cycle. The study is currently recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HQP1351 (oral drug)
What this could lead to: If successful, this could help determine a safe dose of HQP1351 for future studies in treating GIST and other solid tumors.
What could go wrong: This is an early Phase 1 trial focused on safety and dosing, not yet on effectiveness. The drug may not work or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTROINTESTINAL STROMAL TUMOR (GIST) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastrointestinal stromal tumor neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GASTROINTESTINAL STROMAL TUMOR (GIST) SOLID TUMOR, ADULT

Contacts and locations

Locations

Chinese PLA general hospital, Beijing, China
RECRUITING

Beijing, China
Fudan University Shanghai Cancer Center
RECRUITING

Shanghai, China
Guangdong general hospital
RECRUITING

Guangzhou, Guangdong, China
Henan cancer hospital
RECRUITING

Zhengzhou, Henan, China
Sun-Yat Sen University Cancer Center
RECRUITING

Guangzhou, Guangdong, 510060, China
Union Hospital Tongji Medical College of Huazhong University of Science ang Technology
RECRUITING

Wuhan, Hubei, 215316, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.